NasdaqGS - Nasdaq Real Time Price USD

BioMarin Pharmaceutical Inc. (BMRN)

Compare
67.38 -1.00 (-1.46%)
At close: 4:00:02 PM EST
67.38 0.00 (0.00%)
After hours: 4:20:00 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,752,809.00
2,419,226.00
2,096,039.00
1,846,275.00
1,860,455.00
Cost of Revenue
564,818.00
514,854.00
483,669.00
470,515.00
524,272.00
Gross Profit
2,187,991.00
1,904,372.00
1,612,370.00
1,375,760.00
1,336,183.00
Operating Expense
1,875,556.00
1,746,273.00
1,566,406.00
1,450,093.00
1,428,016.00
Operating Income
312,435.00
158,099.00
45,964.00
-74,333.00
-91,833.00
Net Non Operating Interest Income Expense
59,060.00
41,004.00
2,064.00
-4,855.00
-12,699.00
Other Income Expense
19,982.00
-10,538.00
101,550.00
3,846.00
55,462.00
Pretax Income
391,451.00
188,563.00
149,576.00
-75,350.00
-48,997.00
Tax Provision
69,160.00
20,918.00
8,015.00
-11,270.00
-903,026.00
Net Income Common Stockholders
322,291.00
167,645.00
141,561.00
-64,080.00
854,029.00
Average Dilution Earnings
--
--
--
--
8,313.00
Diluted NI Available to Com Stockholders
324,976.00
167,645.00
141,561.00
-64,080.00
862,342.00
Basic EPS
1.70
0.89
0.76
-0.35
4.75
Diluted EPS
1.66
0.87
0.75
-0.35
4.53
Basic Average Shares
189,475.75
187,834.00
185,266.00
182,852.00
180,804.00
Diluted Average Shares
192,825.75
191,595.00
188,963.00
182,852.00
191,678.00
Total Operating Income as Reported
322,409.00
158,097.00
149,562.00
-82,341.00
-43,440.00
Total Expenses
2,440,374.00
2,261,127.00
2,050,075.00
1,920,608.00
1,952,288.00
Net Income from Continuing & Discontinued Operation
322,291.00
167,645.00
141,561.00
-64,080.00
854,029.00
Normalized Income
314,057.76
167,645.00
43,512.39
-57,276.55
818,755.40
Interest Income
75,247.00
58,339.00
18,034.00
10,482.00
16,610.00
Interest Expense
15,593.00
16,741.00
15,377.00
14,744.00
27,480.00
Net Interest Income
59,060.00
41,004.00
2,064.00
-4,855.00
-12,699.00
EBIT
407,044.00
205,304.00
164,953.00
-60,606.00
-21,517.00
EBITDA
506,724.00
309,690.00
266,922.00
47,433.00
83,655.00
Reconciled Cost of Revenue
513,969.00
472,668.00
444,500.00
424,376.00
481,300.00
Reconciled Depreciation
99,680.00
104,386.00
101,969.00
108,039.00
105,172.00
Net Income from Continuing Operation Net Minority Interest
322,291.00
167,645.00
141,561.00
-64,080.00
854,029.00
Total Unusual Items Excluding Goodwill
10,000.00
--
103,600.00
-8,000.00
48,320.00
Total Unusual Items
10,000.00
--
103,600.00
-8,000.00
48,320.00
Normalized EBITDA
496,724.00
309,690.00
163,322.00
55,433.00
35,335.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
1,766.76
--
5,551.39
-1,196.55
13,046.40
12/31/2020 - 7/26/1999

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ALNY Alnylam Pharmaceuticals, Inc.
237.98
-1.07%
 
INCY Incyte Corporation
70.54
-3.54%
 
SRPT Sarepta Therapeutics, Inc.
124.79
-1.17%
 
HALO Halozyme Therapeutics, Inc.
52.80
-1.79%
 
RARE Ultragenyx Pharmaceutical Inc.
42.07
-3.62%
 
IONS Ionis Pharmaceuticals, Inc.
33.46
-1.88%
 
JAZZ Jazz Pharmaceuticals plc
121.41
+0.98%
 
EXEL Exelixis, Inc.
36.02
+4.41%
 
BBIO BridgeBio Pharma, Inc.
29.08
-1.26%
 
REGN Regeneron Pharmaceuticals, Inc.
696.88
-5.00%